Molecular Tumor Board

Since 2020, the multidisciplinary Molecular Tumor Board (MTB) has brought together the expertise and experience of molecular pathologists, oncologists, geneticists, hospital pharmacists, molecular biologists, bioinformaticians, and data managers. Its goal is to harmonize access to molecular analyses and support oncologists in selecting the most appropriate therapies, taking into account the clinical context and tumor biology.

The MTB is responsible for identifying patients eligible for molecular testing, selecting the most appropriate and cost-effective gene panel. It also interprets the data obtained from molecular analyses to define the biological significance and potential therapeutic actionability of genetic alterations, identifying any active drugs. Patients’ clinical and genomic data are discussed collectively to determine the optimal treatment.

These multidisciplinary meetings are held on a weekly basis.